Sandoz opens USD 99 million plant. Sandoz Group stock is valued at CHF 32.0 billion

Published on 10/16/2026 at 09:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz opens a USD 99 million plant on September 29, 2026. Sandoz Group stock costs EUR 81.01 on October 16, 2026 after USD 5.78 billion sales in the first half.

Manufacturing expansion and interim sales

Sandoz opened a USD 99.0 million facility in Lendava on September 29, 2026.
First-half 2026 sales reached USD 5.78 billion, up 9.90 percent year over year.
Sandoz Group stock traded at EUR 81.01 at 9:08 a.m. CEST on October 16, 2026.
Market capitalization stood at CHF 32.0 billion as of October 16, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz Group AG (ISIN CH1243598427) traded at EUR 81.01 at Lang & Schwarz at 9:08 a.m. CEST on October 16, 2026. The company had opened a USD 99.0 million biosimilar development and manufacturing facility in Lendava, Slovenia, on September 29, 2026, according to Finanzen.at.

Plant investment expands capacity

The Lendava site is designed to strengthen Sandoz's in-house production network for biosimilars. The facility is part of a broader manufacturing push that includes more than 300 specialists and a portfolio target of more than 100 biosimilars by 2040, as Simply Wall St reported on October 13, 2026.

The investment matters because biosimilars require complex development, scale and reliable production. Greater internal capacity can support launches, but pricing pressure in generic medicines remains a direct test of future margins.

What do the interim figures show?

Sandoz reported first-half 2026 revenue of USD 5.78 billion, 9.90 percent above USD 5.27 billion in the first half of 2025. Net income fell to USD 109.0 million from USD 377.0 million, according to Simply Wall St.

Three dated company developments

On August 5, 2026, Sandoz reported first-half revenue of USD 5.78 billion. On September 29, 2026, it opened the USD 99.0 million Lendava facility. On October 13, 2026, coverage highlighted the site's role in expanding biosimilar capacity and the longer-term portfolio target of more than 100 products by 2040.

When is the next report?

Sandoz scheduled its nine-month and third-quarter 2026 sales update for October 28, 2026, with the company reiterating full-year guidance for mid- to high-single-digit constant-currency sales growth and core EBITDA margin expansion of about 100 basis points, according to VZ on October 1, 2026.

Stock valuation and next catalyst

Sandoz Group's market capitalization was CHF 32.0 billion as of October 16, 2026. The October 28 sales update will test whether the capacity expansion is being matched by sales growth and improving profitability.

Sandoz Group stock was trading at EUR 81.01 at Lang & Schwarz on October 16, 2026 at 9:08 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.